Abstract:Background: Tacrolimus is a potent calcineurin inhibitor (CNI) that is principally used as a first-line immunosuppressant for the prophylaxis of allograft rejection in liver transplantation (LT) patients. In clinical practice, prescribing the optimal tacrolimus dosage is complicated by its narrow therapeutic index and high pharmacokinetic variability. Thus, performing therapeutic drug monitoring (TDM) of only tacrolimus may not provide optimal drug levels. However, other influential clinical factors affecting tacrolimus levels, such as hemoglobin (Hb), hematocrit, and total bilirubin (TBIL), should be considered while adjusting tacrolimus levels. This case report aims to introduce clinicians and their teams to taking the pharmacokinetic prediction equation into consideration for a better understanding of tacrolimus dosage adjustment during the early postoperative LT. Case presentation: In this case report, an 18-year-old male patient of Thai ethnicity was admitted for orthotropic liver transplantation, and tacrolimus was prescribed as a cornerstone immunosuppressive agent. In the immediate postoperative period, which is the most challenging period in liver transplantation, the population pharmacokinetics predictive equation was clinically used to assist in dosage adjustment of tacrolimus by considering the significant clinical factors in this case. Hemoglobin and total bilirubin levels were deemed significant clinical factors affecting the oral clearance (CL/F) of tacrolimus. First, a decrease in the Hb concentration increases the free drug concentration and therefore increases the CL/F of tacrolimus. Second, an elevated TBIL decreases the biliary excretion of tacrolimus, resulting in a decrease in the CL/F of tacrolimus. Thus, dose optimization of tacrolimus would be accurate when taking the pharmacokinetic prediction equation into consideration. Moreover, the results may contribute to a better understanding of tacrolimus pharmacokinetic variability in each transplant patient during the immediate postoperative course. Conclusions: Hemoglobin and total bilirubin were significant clinical factors influencing the oral clearance of tacrolimus early after liver transplantation. A decrease in the hemoglobin concentration would increase the free drug concentration and therefore increase the oral clearance of tacrolimus. An elevated total bilirubin decreases the biliary excretion of tacrolimus, resulting in a decrease in the oral clearance of tacrolimus.

Metabolic characteristics and usage of tacrolimus in patients subject to living-donor partial liver transplantation

Tacrolimus Dosage Requirements in Living Donor Liver Transplant Recipients with Small-for-size Grafts

A Retrospective Analysis of the Safety and Efficacy of Low Dose Tacrolimus (fk506) for Living Donor Liver Transplant Recipients

Higher Tacrolimus Blood Concentration is Related to Hyperlipidemia in Living Donor Liver Transplantation Recipients

Higher Tacrolimus Blood Concentration is Related to Increased Risk of Post-Transplantation Diabetes Mellitus after Living Donor Liver Transplantation

The Effect of CYP 3A5 Genotypic Analysis of Donor from Cardiac Death Donation on the Individualized Administration of Tacrolimus

Lower Tacrolimus Trough Levels in the Late Period after Living Donor Liver Transplantation Contribute to Improvements in Long-Term Clinical Outcomes.

GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism

Once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in liver transplantation

Relationship Between Oral Doses of Tacrolimus and Changes in Blood Concentration after Liver Transplantation

Application value of Tacrolimus sustained-release capsules in patients after liver transplantation

Pharmacokinetics of Tacrolimus in Early Period Post-Liver Transplantation and Its Interfering Factors

Association of CYP3A5 and C5 Polymorphisms with the Individual Dosage Regimen of Tacrolimus in Chinese Liver Transplantation Recipients During the Early Post-Transplantation Period

A New Donors' Cyp3a5 and Recipients' Cyp3a4 Cluster Predicting Tacrolimus Disposition, and New-Onset Hypertension in Chinese Liver Transplant Patients

Hemoglobin and total bilirubin may affect tacrolimus clearance in liver transplant patient following the early postoperative period: a case report

Effect of Low-Dose Tacrolimus with Mycophenolate Mofetil on Renal Function Following Liver Transplantation.

Application of Immunosuppressive Agents in Children with Pediatric Living-Donor Liver Transplantation

Effects of CYP3A5 Genotypes on Thrombocytopenia in Liver Transplantation Patients Treated with Tacrolimus.

Relationship Between Tacrolimus Blood Level/dose and the Genotype of CYP3A5 after Lung Transplantation

Beneficial Effects of Wuzhi Capsule on Tacrolimus Blood Concentrations in Liver Transplant Patients with Different Donor‐recipient CYP3A5 Genotypes

Association of Hemoglobin Levels, CYP3A5, and NR1I3 Gene Polymorphisms with Tacrolimus Pharmacokinetics in Liver Transplant Patients